Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMission INDuction in very early Rheumatoid Arthritis (REMINDA)
2015-004858-17Phase 4Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of golimumab and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Sustained remission at week 24 after start of tapering. Started Sep 2016; status: terminated.
02
Drugs
golimumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-004858-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004858-17.